CONMED (CNMD) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Maintained | Equal-Weight | $46.00 from $39.00 | Jul 30, 2026 |
| Piper Sandler | Maintained | Neutral | $45.00 from $39.00 | Jul 30, 2026 |
| BMO Capital | Initiated Coverage | Market Perform | $36.00 | Jul 9, 2026 |
| B of A Securities | Downgraded | Neutral → Underperform | $40.00 | Jun 29, 2026 |
| B of A Securities | Maintained | Neutral | $40.00 from $52.00 | May 18, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $39.00 from $42.00 | May 1, 2026 |
| JP Morgan | Maintained | Neutral | $40.00 from $43.00 | Apr 30, 2026 |
| Piper Sandler | Downgraded | Overweight → Neutral | $39.00 from $55.00 | Mar 17, 2026 |
| Needham | Maintained | Hold | — | Jan 29, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $42.00 from $41.00 | Jan 29, 2026 |
| B of A Securities | Maintained | Neutral | $52.00 from $65.00 | Dec 8, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $47.00 from $57.00 | Nov 6, 2025 |
| JP Morgan | Maintained | Neutral | $52.00 from $58.00 | Nov 6, 2025 |
| Piper Sandler | Maintained | Overweight | $55.00 from $68.00 | Nov 6, 2025 |
| Piper Sandler | Maintained | Overweight | $68.00 from $80.00 | Jul 31, 2025 |
| Needham | Downgraded | Buy → Hold | $61.00 | Jun 12, 2025 |
| Needham | Maintained | Buy | $61.00 from $91.00 | May 1, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $57.00 from $70.00 | May 1, 2025 |
| JP Morgan | Maintained | Neutral | $58.00 from $70.00 | May 1, 2025 |
| Stifel | Downgraded | Buy → Hold | $55.00 from $75.00 | Apr 28, 2025 |
Frequently asked questions
What is the price target for CNMD stock?
The average 12-month analyst price target for CONMED (CNMD) is $41.75, with a high estimate of $46.00 and a low of $36.00, across 4 analysts.
Is CNMD a buy, sell, or hold?
Analysts covering CONMED currently average a Hold rating: 0 buy, 6 hold and 2 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CNMD?
The average price target of $41.75 implies 16.55% downside from the last price of $50.03.
What is the latest analyst rating on CNMD?
On Jul 30, 2026, Wells Fargo maintained CONMED at Equal-Weight with a price target of $46.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.